NASDAQ:HURA TuHURA Biosciences Q2 2026 Earnings Results & Report $1.78 +0.02 (+1.08%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more. TuHURA Biosciences beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.14 versus the -$0.1533 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:30 AM ET TuHURA Biosciences EPS ResultsActual EPS-$0.14Consensus EPS -$0.1533Beat/MissBeat by +$0.0133One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersTuHURA Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTuHURA Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TuHURA Biosciences Q2 2026 Earnings FAQ Did TuHURA Biosciences beat earnings estimates for Q2 2026? TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.14 per share for Q2 2026, beating the consensus estimate of -$0.1533. The report was announced on Friday, August 14, 2026. When is TuHURA Biosciences' next earnings date? TuHURA Biosciences' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for TuHURA Biosciences on the company's earnings history page. TuHURA Biosciences Earnings HeadlinesTuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025October 13 at 7:45 AM | prnewswire.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Has Consensus Price Target of $9.00October 7, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 15 at 1:00 AM | Profits Run (Ad)TuHURA Biosciences (NASDAQ:HURA) Stock Falls 2.1% - Here's What HappenedOctober 6, 2026 | americanbankingnews.comTuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyOctober 5, 2026 | prnewswire.comTuHURA Biosciences Draws Additional Funds From Credit FacilitySeptember 24, 2026 | tipranks.comSee More TuHURA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email. Email Address About TuHURA BiosciencesTuHURA Biosciences (NASDAQ:HURA) (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company’s research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors. TuHURA’s lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response. The company is evaluating the program for potential use in combination with other cancer therapies, although its products remain investigational and are not approved for commercial use. The company became publicly traded following a business combination with Kintara Therapeutics and is headquartered in Tampa, Florida. TuHURA is led by James A. Bianco, M.D., who serves as chairman and chief executive officer. Its activities are primarily focused on advancing its oncology pipeline through clinical development and regulatory evaluation.View TuHURA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth Path Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
